| 0.0867 -0.003 (-3.32%) | 04-25 13:07 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.23 |
1-year : | 0.31 |
| Resists | First : | 0.19 |
Second : | 0.27 |
| Pivot price | 0.11 |
|||
| Supports | First : | 0.08 |
Second : | 0.07 |
| MAs | MA(5) : | 0.09 |
MA(20) : | 0.11 |
| MA(100) : | 0.3 |
MA(250) : | 0.5 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.1 |
D(3) : | 2.1 |
| RSI | RSI(14): 33.1 |
|||
| 52-week | High : | 2.7 | Low : | 0.08 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AKAN ] has closed above bottom band by 21.7%. Bollinger Bands are 32.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.09 - 0.09 | 0.09 - 0.09 |
| Low: | 0.09 - 0.09 | 0.09 - 0.09 |
| Close: | 0.09 - 0.09 | 0.09 - 0.09 |
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Mon, 15 Apr 2024
Akanda Corp Pauses Equity Financing Amid Growth Strategy - TipRanks.com - TipRanks
Mon, 15 Apr 2024
Akanda to pause equity financing for thirty days (NASDAQ:AKAN) - Seeking Alpha
Fri, 12 Apr 2024
Akanda Corp Targets Expanding German Cannabis Market - TipRanks.com - TipRanks
Thu, 11 Apr 2024
Akanda Corp. Announces Plan to Integrate Technology Solutions to Capture UK Market - Yahoo Finance
Thu, 11 Apr 2024
Akanda Corp. Strengthens with Strategic Sale - TipRanks.com - TipRanks
Thu, 11 Apr 2024
Akanda Corp. Announces Closing of the Sale of RPK - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 2.21e+006 (%) |
| Held by Institutions | 14 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.105e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -416.6 % |
| Return on Assets (ttm) | -23.6 % |
| Return on Equity (ttm) | -54.3 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 504.22 |
| Sales Per Share | 2.44721e+006 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.02 |
| Dividend | 0 |
| Forward Dividend | 2520 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|